IRD7:00 AMOpus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027Trial Results • Phase 1/2Cohort 1 data release Wed, Sep 9, 2026, 7:00 AM EDTGopusgtx.com
IRD7:00 AMOpus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology ConferencesResults Call • Phase 1/2Results call Wed, Sep 9, 2026, 8:00 AM ETGopusgtx.com
IRD7:00 AMOpus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate UpdateTrial Results • Phase 1/2OPGx-BEST1 Cohort 1 topline data Sun, Sep 6, 2026, 7:00 AM EDTGopusgtx.com
IRD7:00 AMOpus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal DiseaseEnrollment • Phase 3Enrollment milestone Mon, Aug 3, 2026, 7:00 AM EDTGopusgtx.com